Aphios Corporation today announced that it received notification of
allowance for a United States Patent entitled "Nanoencapsulated
Delta-9-Tetrahydrocannabinol" for the oral delivery of cannabinoids such
as ?"9-THC in biodegradable polymer nanoparticles.
According to Dr. Trevor P. Castor, co-inventor of the technology, "The
patented technology will be utilized in the manufacturing of APH-0812
for pain and cachexia in AIDS and cancer patients, and APH-1305 for
Multiple Sclerosis and other CNS disorders. The nanotech formulation of
?"9-THC will also have applicability in several other chronic diseases
such as obesity, smoking cessation and schizophrenia."
In the currently marketed oral formulation, synthetic ?"9-THC
(Dronabinol®) is dissolved in sesame seed oil and is commercially
available as an oral capsule (Marinol®). Oral administration causes
slow, variable ?"9-THC uptake. In addition, it also requires drug
administration several times a day because of first pass metabolism.
For the novel patented formulation, pharmaceutical grade ?"9-THC and
other cannabinoids from Cannabis sativa with a >99% purity are
first manufactured following cGMP utilizing Aphios' patented SFS-CXP
manufacturing technology platform. Our scientists and engineers then
utilize Aphios' patented SFS-PNS polymer nanospheres technology platform
to encapsulate ?"9-THC in a biodegradable polymer. Nanoencapsulation
protects ?"9-THC transport to the stomach, enhances its passage across
the stomach lining of the gut and protects it from first pass metabolism
in the liver. Nanoencapsulation slows the release of ?"9-THC, controlling
the amount of drug in the bloodstream and reducing the frequency of drug
administration during the day. Alternatively, the nanoformulation will
be utilized to deliver ?"9-THC and other cannabinoids from a
subcutaneously implanted depot.
Aphios® Corporation (www.aphios.com),
Woburn, MA is a clinical stage biotechnology company developing green,
enabling technology platforms for improved drug discovery and
manufacturing, nanotechnology drug delivery and pathogenic drug safety.
Based on these platforms, Aphios is developing enhanced therapeutic
products for health maintenance, disease prevention and the treatment of
certain cancers, infectious diseases and central nervous system
Research leading to these discoveries were supported by grants from the
National Cancer Institute (NCI) and the National Institute on Drug Abuse
(NIDA), National Institutes of Health (NIH). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NCI, NIDA or NIH.
Trevor P. Castor, Ph.D., CEO, 781-932-6933